Comprehensive metabolomic plasma profiling identifies novel potential diagnostic biomarkers in patients with advanced neuroendocrine tumors

#3271

Introduction: NETs are heterogeneous neoplasms that have the capacity to secrete hormones or bioactive molecules. Dysregulated metabolism is one of the key hallmarks of cancer and the altered expression of metabolic enzymes is deeply involved in tumor development, progression, and metastasis.

Aim(s): To conduct a comprehensive characterization of metabolomic profile of NET patients to identify dysregulated metabolic pathways and new diagnostic biomarkers of potential clinical use.

Materials and methods: GC-MS, CE-MS and LC-MS was performed in the plasma of 77 patients with advanced lung and GI NETs, and 68 control patients. Univariate and multivariate analysis were performed to assess differences between NETs and controls. Related pathways were explored by Metaboanalyst 4.0. ROC and PLS-DA models were built to discover potential diagnostic biomarkers (AUC>0.85 or VIP>1 and pcorr (>0.5).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Soldevilla B, Lens-Pardo A, López-López �, Carretero-Puche C, La Salvia A,

Keywords: NETs, metabolic signalling, plasma metabolites, diagnostic biomarker,